NSCLC (NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study tests a new approach for people with early-stage non-small-cell lung cancer that can be removed with surgery. Before surgery, participants will receive a short course of targeted radiation (SBRT) combined with an immunotherapy drug (QL1706) and chemotherapy. The goal i…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
New drug duo aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study tests whether giving a high dose of the targeted drug firmonertinib together with bevacizumab before surgery can improve outcomes for people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). About 62 participants will receive the drug combination, then…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
New targeted pill takes on chemotherapy for KRAS-mutant lung cancer
Disease control Not yet recruitingThis study tests a new drug, JMKX001899, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried at least one prior treatment. The goal is to see if the …
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Jemincare • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for lung cancer patients: drug combo targets tumors after first therapy fails
Disease control Not yet recruitingThis study tests a combination of two drugs, sacituzumab tirumotecan and furmonertinib, in 45 adults with advanced non-small cell lung cancer that has a specific genetic mutation (EGFR). The cancer must have stopped responding to a first-line targeted therapy. The goal is to see …
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 19, 2026 11:49 UTC
-
New drug duo shows promise in shrinking lung tumors before surgery
Disease control Not yet recruitingThis study tests whether giving two drugs (sacituzumab tirumotecan and toripalimab) before surgery can shrink tumors in people with stage II-IIIB non-small cell lung cancer. About 38 adults whose cancer lacks certain genetic changes will receive the combination, then have surgery…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 18, 2026 12:00 UTC
-
New trial aims to stop cancer from accelerating on immunotherapy alone
Disease control Not yet recruitingThis study is for people with advanced non-small cell lung cancer that has a high level of a protein called PD-L1. Some patients with a specific blood marker are at risk of their tumors growing faster when treated with immunotherapy alone. The trial will compare standard immunoth…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Università Vita-Salute San Raffaele • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Lung cancer study aims to decode immune secrets
Knowledge-focused Not yet recruitingThis study will collect and analyze tumor samples from 500 people with advanced non-small cell lung cancer to see how immune markers and gene activity relate to treatment response. Participants give biopsies before and during immunochemotherapy. The goal is to learn, not to test …
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated May 22, 2026 13:55 UTC